Celonic AG
http://www.celonic.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Celonic AG
Tech Transfer Roundup: BridgeBio’s R&D Efforts Span New Seven New Agreements
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
Early Results For Therapyx/Intravacc's Vaccine May Herald Progress In Gonorrhea Prevention
Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.
Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Contract Manufacturing Organization
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice